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in our previous study. Patients provided a fecal sample and completed five question-
naires	to	assess	their	symptoms	and	quality	of	life	at	1	year	after	FMT.	The	dysbiosis	
index	(DI)	and	fecal	bacterial	profile	were	analyzed	using	a	16S	rRNA	gene-	based	DNA	
probe	hybridization.	The	 levels	of	 fecal	short-	chain	 fatty	acids	 (SCFAs)	were	deter-
mined by gas chromatography.
Results: There	was	 a	 persistent	 response	 to	 FMT	 at	 1	 year	 after	 treatment	 in	 32	




life were improved at 1 year compared with after 3 months. These findings were ac-
companied	by	comprehensive	changes	in	the	fecal	bacterial	profile	and	SCFAs.
Conclusions: Most	of	 the	 IBS	patients	maintained	a	 response	at	1	year	after	FMT.	
Moreover,	 the	 improvements	 in	 symptoms	 and	 quality	 of	 life	 increased	 over	 time.	
Changes	in	DI,	fecal	bacterial	profile	and	SCFAs	were	more	comprehensive	at	1	year	
than	after	3	months.	www.clini	caltr	ials.gov	(NCT03822299).
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1  |  INTRODUC TION
Irritable	bowel	syndrome	(IBS)	is	a	common	chronic	gastrointestinal	
disorder,	with	IBS	patients	representing	12–	14%	of	primary-	care	pa-
tient	visits	and	28%	of	referrals	to	gastroenterologists.1-	5 The current 
treatments used in the clinic focus on symptom relief. The intestinal 
bacterial profile of IBS patients deviates from that of healthy sub-
jects,	with	a	low	diversity	and	or	abnormal	bacteria	profiles	(dysbio-
sis).	However,	there	is	disagreement	regarding	the	distinct	microbial	
signature of IBS patients.6 The intestinal microbiota is considered to 
be one of the factors that plays crucial roles in the etiology of IBS.1
A	 recent	 randomized,	 double-	blind,	 placebo-	controlled	 study	
performed by our group found that fecal microbiota transplantation 
(FMT)	was	effective	in	improving	the	abdominal	symptoms,	fatigue,	
and quality of life in IBS patients.7 These changes were accompanied 
by changes in the fecal bacterial profile.7	 However,	 these	 results	
were	observed	only	at	3	months	after	FMT,	and	several	questions	
remained	 to	 be	 answered,	 such	 as	 whether	 the	 clinical	 effect	 of	
FMT	is	sustained	over	the	long	term,	whether	the	bacterial	profile	




2  |  MATERIAL S AND METHODS
2.1  |  Study design
The design of this has been described in detail previously.7	In	brief,	
patients provided a fecal sample and completed five questionnaires 
to	 assess	 their	 symptoms	 and	quality	 of	 life	 at	 baseline,	 and	 then	
provided another fecal sample and completed a new set of question-
naires	at	1	month	after	FMT.	They	also	completed	an	additional	set	
of	questionnaires	at	3	months	after	FMT.7	At	1	year	after	FMT,	the	
patients completed another set of the questionnaires and provided 
a	new	fecal	sample.	The	patients	were	asked	to	keep	a	diary	to	re-
cord bowel habits and register any adverse events. Polyethylene gly-
col	and	 loperamide	were	allowed	during	 the	previous	 randomized,	
double-	blind,	 placebo-	controlled	 study	 as	 rescue	medication.	 The	
patients	were	asked	to	continue	using	this	rescue	medication	and	to	
record	their	consumption.	They	were	asked	also	to	record	the	use	of	
other IBS medication. The patients continued with their medication 
listed	in	Table	1	including	proton-	pump	inhibitor	(PPI).
2.2  |  Patients
This	 study	 included	 77	 of	 the	 91	 IBS	 patients	who	 responded	 to	
FMT	in	our	previous	study,	defined	as	a	decrease	of	≥50	points	 in	









characteristics of these patients at baseline are given in Table 1.
The	inclusion	and	exclusion	criteria	of	the	present	study	are	also	
provided in our previous report.7	In	summary,	the	inclusion	criteria	
were	being	aged	18	to	85	years	and	having	moderate-	to-	severe	IBS	
symptoms,	which	were	defined	as	an	IBS-	SSS	total	score	of	≥175.	The	
exclusion	 criteria	were	 the	 presence	 of	 systemic	 disease,	 immune	




2.3  |  Donor characteristics and fecal sample 
collection, preparation, and administration




analysis were performed on 63 fecal samples: 32 patients belong-
ing	 to	 the	 30-	g	 group	 (28	 responders	 and	 4	 non-	responders)	 and	
31	patients	belonging	to	the	60-	g	group	(27	responders	and	4	non-	




30 g of donor feces and the second group received 60 g. The fecal 
Key Points
•	 A	 recently	 published	 randomize	 controlled	 trial	 (RCT)	
from our group showed that fecal microbiota transplan-
tation	(FMT)	improves	IBS	symptoms	and	the	quality	of	
life	 at	 3	months	 after	 treatment.	Mild	 self-	limited	 ad-
verse events were observed.
• The improvement in symptoms and quality of life in this 
RCT	was	accompanied	marked	changes	in	the	fecal	pro-
files of active treated patients.
•	 Most	responders	to	FMT	after	3	months	maintain	their	
response	after	1	year.	The	effects	of	FMT	on	IBS	symp-
toms,	 the	 quality	 of	 life,	 and	 the	 changes	 in	 the	 fecal	
bacteria	increase	over	time.	Furthermore,	the	microbial	
metabolism changed from a saccharolytic to a proteo-
lytic fermentation pattern in IBS patients at 1 year after 
FMT.
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material was thawed for 2 days at 4℃,	mixed	with	40	mL	of	 ster-
ile	saline,	filtered,	and	administered	to	the	distal	duodenum	via	the	
working	channel	of	a	gastroscope.
2.4  |  Symptoms and quality of life assessment





considered to be in complete remission.8 Quality of life was meas-
ured	using	the	IBS	Quality	of	Life	(IBS-	QoL)	questionnaire	and	the	
Short-	Form	Nepean	Dyspepsia	Index	(SF-	NDI)	questionnaire.10-	12
2.5  |  Fecal bacterial analysis
The	fecal	bacteria	were	analyzed	using	the	GA-	map	Dysbiosis	Test® 
method as described in detail previously.13,14	In	brief,	the	test	uses	
the	 16S	 rRNA	 gene	 to	 measure	 the	 fluorescence	 signals	 for	 48	
bacterial	markers.	 This	method	was	 used	 for	 calculating	 both	 the	
bacterial	 profile	 and	 dysbiosis	 index	 (DI).	 The	 48	 bacterial	 mark-
ers	detected	bacteria	within	five	phyla	(Firmicutes,	Proteobacteria,	
Bacteroidetes,	Tenericutes,	and	Verrucomicrobia)	that	cover	10	bac-
terial	classes,	36	genera,	and	32	species.13 This test assesses >300 
bacteria	 at	 different	 taxonomic	 levels.14 The DI was measured on 
a	5-	point	scale	from	1	(normal)	to	five	(severe	dysbiosis),	where	DI	
values >2 indicate the presence of dysbiosis.13












2.7  |  Statistical analysis






comparisons	 test	 as	 a	 post-	test.	 The	Kruskal–	Wallis	 test	was	 also	
used	 to	 detect	 difference	 in	 the	 bacterial	markers	 at	 baseline	 be-
tween	responders,	patients	in	remission,	and	patients	who	relapsed	
1	year	after	FMT.	The	correlations	between	the	changes	in	bacterial	
profiles	 and	 the	 IBS-	SSS	 and	 FAS	 scores	were	 analyzed	 using	 the	
non-	parametric	 Spearman	 test	 and	 reported	 as	 correlation	 coeffi-
cient	 (r),	p value and Bonferroni adjusted p values. Differences in 
TA B L E  1 Baseline	characteristics	of	the	included	patients
Overall 30- g FMT 60- g FMT
Number 77 37 40
Age,	years 39.6	±	11.6 39.6	±	11.6 38.1	±	14.4
Sex,	female/male 62/15 29/8 33/7
IBS-	D 32 17 15
IBS-	C 25 11 14
IBS-	M 20 9 11
IBS	duration,	years 15.5	±	7.9 17.2	±	9.3 14.7	±	5.7
IBS-	SSS	score 311.3	±	72.5 322.8	±	64.1 315.3	±	72.5
FAS	score 31.3	±	4.9 31.4	±	5.1 31.2	±	4.8
PPI medication 35	(45.5) 18	(48.6) 17	(42.5)
Birth-	control	medication 48	(62.3) 22(59.5) 26	(65.0)
Antimigraine	medication 7	(9.1) 4	(10.8) 3	(7,5)
Medication	against	asthma/allergies 11	(14.3) 4	(10.8) 7(17.5)











Wilcoxon	test.	Adjusted	p values were calculated using Bonferroni 
correction,	 with	 p < 0.05 considered significant. Scaled principal 
components	analysis	(PCA)	of	log-	transformed	fluorescence	signals	
was	 performed,	 with	 the	 results	 visualized	 using	 different	 colors	
for	different	groups,	together	with	ellipses	that	covered	80%	of	the	
F I G U R E  1 Total	scores	of	IBS-	SSS	(A-	D),	of	FAS	(E-	H)	and	of	IBS-	QoL	(I-	L)	in	the	IBS	patients	who	received	30	g	transplant	(30-	g	group),	
60	g	transplant	(60-	g	group),	responder	(patients	who	exhibited	a	decrease	of	≥50	points	in	the	IBS-	SSS	total	score	1	year	after	FMT)	and	
relapse	(patients	who	responded	at	3	months,	but	did	not	respond	1	year	after	FMT)	groups	at	baseline,	at	3	months	and	1	year	after	FMT.	
*p < 0.05; **p < 0.01; ****p < 0.0001
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samples within each group. These analyses were performed using 
GraphPad	 Prism	 software	 (version	 8.4.1,	 La	 Jolla)	 and	 R	 (version	
3.6.3,	R	Foundation	for	Statistical	Computing).
2.8  |  Ethics
The	 study	was	 approved	 by	 the	 Regional	 Committee	 for	Medical	
and	 Health	 Research	 Ethics	West,	 Bergen,	 Norway	 (approval	 no.	
2017/1197/REK	vest).	All	 subjects	 provided	both	oral	 and	written	
consents to participate. The study was registered at www.clini caltr 
ials.gov	(NCT03822299).
All	authors	had	access	to	the	study	data	and	reviewed	and	ap-
proved the final version of the manuscript.
3  |  RESULTS






in	 complete	 remission,	 compared	 with	 11	 (27.5%)	 after	 3	 months	
(p =	0.1).
All	 the	 relapsed	 patients	 (n	 =	 10)	 used	 regularly	 medications.	
Four	patients	used	loperamide,	two	patients	used	polyethylene	gly-
col,	and	two	patients	used	both	polyethylene	glycol	and	loperamide.	
The remaining two patients used linaclotide and prucalopride. In the 
patients	 that	 maintained	 response,	 two	 patients	 used	 loperamide	
only once during the following period and one patient used polyeth-
ylene glycol twice.
3.2  |  Abdominal symptoms, fatigue, and 
quality of life
The	maintained	 response	 in	 females	was	90.3%	and	 in	males	was	
86.7%	and	the	complete	remission	rate	was	40.3%	 in	 females	and	
33.3%	 in	 males.	 The	 response	 rate	 and	 the	 complete	 remission	
rates	did	not	differ	significantly	between	females	and	males	(p = 0.6 
and	0.8,	respectively).	The	maintained	response	rates	were	90.6%,	
88.0%,	and	90.0%	in	IBS-	D,	IBS-	C,	and	IBS-	M	patients,	respectively.	
The	 complete	 remission	 rates	were	41%,	40%,	 and	30%	 in	 IBS-	D,	













C,	 and	 IBS-	M,	 respectively.	 The	 IBS-	SSS	 total	 score	did	 not	 differ	
significantly	between	the	IBs	sub-	types	(p =	0.5).
The total score for the Birmingham IBS Symptom Questionnaire 
and the scores in its three domains were significantly lower 
than	 those	 at	 baseline	 (Table	 S1).	 There	was	 no	 difference	 in	 the	
TA B L E  2 IBS-	SSS	total	score	and	the	scores	for	its	four	subitems	after	FMTH
Time Group Total score Subitem 1 Subitem 2 Subitem 3 Subitem 4
0 30-	g	FMT 322.8	±	64.1 113.6	±	39.2 55.0	±	25.4 76.4	±	19.2 75.6	±	17.8
60-	g	FMT 308.2	±	79.8 106.5	±	45.8 56.8	±	27.2 80.0	±	20.3 75.6	±	20.8
3 months 30-	g	FMT 153.1	±	82.1a  53.7	±	38.9a  30.5	±	21.7a  44.6	±	29.7a  45.3	±	30.9a 
60-	g	FMT 126.9	±	95.5a  56.5	±	47.5a  30.4	±	26.4a  35.3	±	27.5a  40.3	±	27.5a 
1 year 30-	g	FMT 167.0	±	115.9a  59.0	±	54.9a  27.3	±	22.6a  45.1	±	30.0a  41.5	±	31.8a 
60-	g	FMT 119.4	±	105.3a  41.7	±	50.5a  19.4	±	20.2a  30.0	±	27.9a  30.9	±	28.2a 
Note: Data	are	mean	±	SD	values.
Subitems:	1,	abdominal	pain;	2,	abdominal	distension;	3,	dissatisfaction	with	bowel	habits;	4,	interference	with	quality	of	life.
ap < 0.0001 compared with baseline.
TA B L E  3 FAS	scores	in	FMT-	treated	patients.





0 30-	g	FMT 31.4	±	5.1 16.0	±	3.0 15.6	±	2.8
60-	g	FMT 31.2	±	4.8 15.9	±	2.8 15.5	±	2.7
3 months 30-	g	FMT 26.8	±	5.8b  13.3	±	3.5 13.5	±	3.0
60-	g	FMT 27.0	±	6.3b  14.0	±	3.5b  13.0	±	3.1a 
1 year 30-	g	FMT 16.2	±	6.5c,d  8.9	±	3.9c,d  7.6	±	3.3c,d 




cp < 0.0001 compared with baseline.
dp < 0.0001 compared with 3 months.
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Birmingham IBS Symptom Questionnaire total score or its three do-










FMT	 in	 the	 30-	g	 FMT	 group,	 60-	g	 FMT	 group,	 and	 responders	
compared	with	those	at	baseline	(Figure	1	and	Table	4).	In	addition,	
the	 IBS-	QoL	 total	 score	was	 significantly	 higher	 at	 1	 year	 than	 at	





















The levels of 10 bacteria groups differed significantly between 
baseline	 and	 1	 year	 after	 FMT	 in	 patients	 who	 received	 FMT	
(Table	5).	In	the	30-	g	FMT	group,	the	levels	of	three	bacteria	were	
significantly	 increased	 at	 1	 year	 after	 FMT:	 Bacteroides stercoris,	
Alistipes	 spp.,	 and	Bacteroides spp. & Prevotella spp. The levels of 
these	bacteria	were	correlated	inversely	with	both	the	IBS-	SSS	and	
FAS	 total	 scores	 (Table	S3).	The	 levels	of	Eubacterium biforme and 
Parabacteroides	spp.	also	increased	significantly	at	1	year	after	FMT,	
but	 they	were	not	correlated	with	either	 the	 IBS-	SSS	or	FAS	 total	
score	(Table	S3).
In	 the	60-	g	FMT	group	 (N	 =	31),	 the	 levels	of	Bacteroides Spp. 
& Prevotella spp,	Alistipes	spp.,	Bacteroides stercoris,	Parabacteroides 
spp.,	and	Bacteroides zoogleoformans	 increased	at	1	year	after	FMT	
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for relapses. Bacteria in the patients who 
received	30-	g	and	60-	g	FMT	are	indicated	
using	circles	and	triangles,	respectively.	
Ellipses of different colors enclose 
approximately	80%	of	the	samples	
within the different groups. The bacterial 
profiles	of	the	FMT-	treated	patients	are	
grouped more to the right along the first 
PCA	axis
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of Bacteroides zoogleoformans	(Table	S4).	On	the	other	hand,	the	lev-




after	FMT	 (Table	S5).	The	 levels	of	 these	bacteria	were	correlated	
significantly	with	the	IBS-	SSS	and	FAS	total	scores,	with	the	excep-
tions of Parabacteroides	 spp.,	 Shigella spp. & Escherichia	 spp.,	 and	
Dorea spp.
In	 patients	 exhibiting	 complete	 remission	 at	 1	 year	 after	 FMT,	
the levels of the following bacteria were significantly increased: 
Bacteroides spp. & Prevotella	spp.,	Alistipes	spp.,	and	Bacteroides ster-




The only bacteria that differed at baseline between relapsed pa-
tients,	patients	in	remission	and	responders	were	Alistipes spp. The 
level of Alistipes spp. was significantly lower in the relapsed patients 
than	in	the	patients	with	remission	and	responders	(p =	0.008,	ad-
justed p =	0.15)	(Figure	S1).
3.4  |  Fecal SCFA levels




In	 the	patients	exhibiting	 complete	 remission	and	 responders,	 the	






3.5  |  Adverse events
Apart	from	the	mild	intermittent	abdominal	pain,	diarrhea	and	con-





The present findings indicate that most of the patients who re-
sponded	 3	months	 after	 FMT	 remained	 responders	 after	 1	 year.7 
Furthermore,	 there	 were	 more	 patients	 exhibiting	 clinically	 com-
plete	remission	at	1	year	after	FMT	than	after	3	months.7	Moreover,	
the abdominal symptoms and fatigue were significantly less severe 
and the quality of life was significantly better at 1 year than at 
3	months	after	FMT.7	Thus,	it	seems	that	the	effect	of	FMT	intensi-
fied in those who remained responding after 1 year. The finding that 




was	no	difference	between	 IBS	 sub-	types	 regarding	 the	 response	
rate	or	 IBS	symptoms	1	year	following	FMT.	 In	contrast	to	the	re-
cently	published	observation,17 the response rate and IBS symptoms 
did not differ between females and males in the present study.
The	DI	did	not	 improve	at	1	month	after	FMT	 in	our	previous	
study,7	whereas	 it	 had	 improved	 at	 1	 year	 after	 FMT	 in	 the	pres-
ent study. This indicates that the intestinal bacterial diversity had 
Prob bacteria markers Baseline 1 year after FMT p Adjusted p
206 Bacteroides spp. & 
Prevotella spp.
334	(9–	1349) 944	(106–	1330) <0.001 <0.001
Alistipes	spp. 43	(2–	512) 228	(2–	512) <0.001 <0.001




84	(5–	907) 22	(2–	732) <0.001 <0.001
210 Parabacteroides spp. 6	(2–	137) 38	(2–	248) <0.001 <0.001
208 Bacteroides 
zoogleoformans
20	(2–	137) 45	(2–	248) <0.001 0.001
404 Shigella spp. & 
Echerichia spp.
20	(2–	1167) 2	(2–	725) <0.001 0.002
314 Eubacterium hallii 151	(8–	466) 102	(41–	777) <0.001 0.006
300	Firmicutes	spp. 468	(68–	1080) 677	(143–	1304) <0.001 0.016
500 Proteobacteria spp. 45	(16–	1306) 29	(11–	376) <0.001 0.038
Note: Data	are	median	(range)	values.
TA B L E  5 Bacteria	whose	levels	
differed significantly between baseline 
and	1	year	after	FMT	in	all	patients	who	
received	FMT









that are resistant to bile and have limited ability to ferment carbo-
hydrates.18 Alistipes spp. levels in the relapsed patients were signifi-
cantly lower at baseline than in responders and patients in remission 





these findings suggest that Alistipes spp.— which belong to the phy-
lum Bacteroidetes— play a central role in the improvements seen 
after	FMT.	Further	investigations	are	needed	to	clarify	such	a	role.
The	 fecal	 SCFAs	 in	 IBS	 patients	 differ	 from	 those	 in	 healthy	
subjects,	and	it	has	been	suggested	that	this	difference	plays	a	role	
in the pathophysiology of IBS.19 It has been reported recently that 
FMT	increases	the	fecal	SCFA	levels	in	IBS	patients	at	1	month	after	







in patients who relapsed. These results suggest an overall shift of 
the	 microbial	 metabolism,	 from	 a	 saccharolytic	 to	 a	 proteolytic	
fermentation	 pattern,	which	 is	 conceivably	 of	 pathophysiological	
relevance.21 The reduction in acetic acid levels in responders and 
patients	in	the	60-	g	FMT	group	may	be	particularly	relevant	since	
acetic acid has been found to induce visceral hypersensitivity in ro-
dents.22	It	is	noteworthy	that	similar	changes	of	the	SCFAs	profile	
have been demonstrated previously in patients with IBS following 
adherence	 to	 a	 low-	FODMAP	 (fermentable	 oligo-	,	 di-	,	 monosac-
charides,	and	polyols)	diet,	an	 intervention	that	 is	also	associated	
with relief of IBS symptoms.23 The changes observed here in the 
fecal	 SCFAs	may	be	 caused	by	either	 changes	 in	diet	or	 changes	
in	 the	 intestinal	bacterial	profile.	However,	since	the	patients	did	




There	 were	 no	 reported	 adverse	 events	 at	 1	 year	 after	 FMT,	
which means that this treatment can be considered to be safe. 
However,	one	should	keep	in	mind	that	the	patients	included	in	this	
study	 did	 not	 have	 systemic	 disease,	 immune	 deficiency	 (or	were	
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The	 major	 limitation	 of	 this	 study	 is	 that	 it	 did	 not	 follow-	up	
the	 placebo	 group	 in	 our	 previous	 RCT	 study.	 In	 an	 earlier	 study,	






riod. Other limitations of this study were that it investigated only a 
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